The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBloomsbury Share News (BMY)

Share Price Information for Bloomsbury (BMY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 546.00
Bid: 542.00
Ask: 548.00
Change: 10.00 (1.87%)
Spread: 6.00 (1.107%)
Open: 538.00
High: 546.00
Low: 536.00
Prev. Close: 536.00
BMY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday tips round-up: Bloomsbury, Harvey Nash, Avingtrans...

Wed, 01st Jun 2011 06:31

The headline figures in Bloomsbury's results at the end of last week were far from inspiring. But the real highlight of the update was the news that sales of electronic books had rocketed. Of course, the rise of e-books does present challenges for publishers. The most obvious will be the need for companies such as Bloomsbury to be agile enough to deal with the globalisation of the book trade as e-readers spread around the world. Bloomsbury does not deserve to be sold, but the valuation makes us wary of buying at this point. Hold, says the Independent.As the Times has written before, Harvey Nash is one of the more reliable ways of taking the temperature of the corporate world, because the performance of this headhunter and recruitment specialist reflects the confidence of big companies and their willingness to take on expensive new staff. At present, and in contrast to some of the gloomier macroeconomic trends, the patient is in fine fettle. Nash's first quarterly update finds revenues up 23% year-on-year, gross profits up 22% and pre-tax profits 32% higher. From here on, those growth figures will look less impressive, set against strong comparables last year. The shares, up 2.75 at 88p, now sell on almost 14 times this year's earnings, which looks high enough. A strong hold, says the Times.Similar to many other engineering companies, Avingtrans, over the past year, has seen its business and share price recover as the global economy climbed out of recession. The interim results were good and were accompanied by the guidance that the full-year numbers would be ahead of expectations and there is no reason to doubt that this will be the case. However, it is Sigma China, part of the aerospace division, which has the most exciting prospects given the significant growth anticipated in the Chinese aerospace industry over the next two decades. The Scotsman says that the group is not just offering a cyclical recovery and recommends a buy.Renold's full-year figures were slightly below the estimates pencilled in by FinnCap analysts at the time of the Manchester-based engineer's last update, which could have been part of the reason why the stock fell last night. However, we think a more plausible trigger is the rally since the slump seen in early March. Indeed, even after the pullback, Renold remains well above the levels seen just two months ago. Moreover, the figures were hardly horrific, according to the Independent, which recommends a buy.The ordeal is almost over at First Artist Corporation. The company has been dragged down by a range of unprofitable peripheral assets. These have now been sold, one of them to the former management, and the group is out of financial planning, sports, management, Scandinavia and the rest, focused firmly on Dewynters and Spot and Company of Manhattan, which runs a similar business in New York. The company is now being renamed Pivot Entertainment. The shares were 1p higher at 30.25p yesterday; bulletin board postings suggesting they could double or more from here should be taken with a huge pinch of salt, though, says the Times.---BCPlease note: Digital Look provides a round-up of news, tips and information that is impacting share prices and the market. Digital Look cannot take any responsibility for information provided by third parties. This is for your general information only as not intended to be relied upon by users in making an investment decision or any other decision. Please obtain a copy of the relevant publication and carry out your own research before considering acting on any of this information.
More News
26 Mar 2018 21:56

Reuters Health News Summary

Following is a summary of current health news briefs. Biohaven plunges as investors pit migraine data against Allergan's drug Biohaven Pharmaceutical Holding said its acute two a

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 13:56

Reuters Health News Summary

Following is a summary of current health news briefs. Singapore pharma on recovery path after worst output in decades Singapore's among

Read more
26 Mar 2018 07:23

UPDATE 1-Roche's Tecentriq cocktail notches another lung cancer success

ZURICH, March 26 (Reuters) - Roche's immunotherapy Tecentriq combined with other drugs boosted lung cancer patients' survival versus an older cocktail, the Swiss trial

Read more
25 Mar 2018 14:15

Israel to launch Big Data health project

By Maayan Lubell JERUSALEM, March 25 (Reuters) - Israel will invest nearly 1 billion shekels ($287 million) in a to a

Read more
20 Mar 2018 07:05

UPDATE 1-Roche says Tecentriq, chemo cut risk of death in type of lung cancer

ZURICH, March 20 (Reuters) - Roche's immunotherapy Tecentriq plus chemotherapy cut the risk of disease worsening or death in advanced squamous lung cancer, but it did not

Read more
19 Mar 2018 17:59

Bloomsbury Publishing Expecting Profitability To Beat Expectations

LONDON (Alliance News) - Bloomsbury Publishing PLC said on Monday it expects its full-year profit and revenue to both be ahead of expectations.For the year ending 28 to

Read more
20 Jan 2017 09:08

Bloomsbury Publishing Says Chairman Salz To Step Down In July

Read more
27 Oct 2016 07:43

Bloomsbury Publishing Sees Stronger Second Half As Trading In Line

Read more
13 Jul 2016 12:55

Bloomsbury Publishing plots expansion into B2B market

(ShareCast News) - Harry Potter publisher Bloomsbury Publishing held a capital markets day for investors and analysts on Wednesday to present plans to enter the business-to-business market, while also confirming first-quarter trading remained in line with full year expectations. Bloomsbury unveiled

Read more
13 Jul 2016 08:20

Bloomsbury Publishing Says Full Year Trading To Meet Expectations

Read more
12 Jul 2016 15:11

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jul 2016 15:00

UK Shareholder Meetings Calendar - Next 7 Days

Read more
19 May 2016 12:43

Bloomsbury moves towards digital B2B after strong FY

(ShareCast News) - Bloomsbury, the publisher behind the Harry Potter phenomenon, has turned in an overall strong set of full-year results and launched a 2020 strategy to move into digital B2B publishing. It booked a full-year pretax profit of £10.36m, from a year-earlier profit of £9.60m, with reven

Read more
19 May 2016 08:18

Bloomsbury To Reoganise Divisions As Profit Lifted By Children's Books

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.